ILiAD Biotechnologies
PrivateLast Round
Series B
Feb 10, 2026
Est. Valuation
$171M
Total Funding Raised
$228.13M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
ILiAD Biotechnologies operates in Healthcare & Life Sciences and is based in Weston, Florida. Its latest recorded funding round was a Series B round in February 2026.
ILiAD Biotechnologies is a biotechnology company that develops a medical vaccine aimed at preventing and treating diseases caused by Bordetella pertussis by inducing the immune system to produce protective antibodies against infections like whooping cough.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ILiAD Biotechnologies Comparables
Compare ILiAD Biotechnologies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Codagenix | 77% | |
| Sanofi | 76% | |
| CyanVac LLC | 71% |
For institutional investors. Book with your work email.
ILiAD Biotechnologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 10, 2026 | ||||
| Seed | Oct 21, 2022 | ||||
| Series D | Sep 6, 2022 | ||||
| Grant | Apr 26, 2022 | ||||
| Convertible Debt | Mar 12, 2021 | ||||
Seed | Nov 1, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ILiAD Biotechnologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series B |
| RA Capital Management | Series B |
| National Institute of Allergy and Infectious Diseases | Grant |
| Knott Partners, LP | Series D |
| SDS Capital Group | Series C |
| Seedlings Life Science Ventures | Series C |
| BNP Paribas Asset Management | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 38% MoM.
- Jul 25, 2026
Monthly visitors increased 44% MoM, reaching 2.2K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 11, 2026
ILiAD Biotechnologies, Inc. is developing BPZE1 and other technologies to prevent and treat disease caused by Bordetella pertussis, working with scientists and research organizations to address limitations of existing pertussis vaccines and validate its technologies through human clinical trials.
- hiresAug 11, 2026
ILiAD Biotechnologies, Inc. adds Jim Wassil, chief operating officer at Vaxcyte, as an independent board member on Aug 11th '26, as the company advances its pertussis vaccine program.
- hiresAug 11, 2026
ILiAD Biotechnologies, Inc. adds Bill Warren, former global head of antigen design at Sanofi Vaccines, as an independent board member on Aug 11th '26.
- hiresAug 11, 2026
ILiAD Biotechnologies, Inc. appoints Antony Blanc as chief business officer to oversee business development, commercial and long-term value creation initiatives on Aug 11th '26.
For institutional investors. Book with your work email.
ILiAD Biotechnologies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ILiAD Biotechnologies's valuation, stock price, and market status.
Is ILiAD Biotechnologies a public or private company?
ILiAD Biotechnologies is a private company.
What is the current stock price of ILiAD Biotechnologies?
ILiAD Biotechnologies is a private company, so its shares have no public market price. Caplight tracks ILiAD Biotechnologies's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ILiAD Biotechnologies worth (valuation)?
ILiAD Biotechnologies's valuation is estimated at $171.0M based on funding round data.
Can I buy ILiAD Biotechnologies stock?
ILiAD Biotechnologies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ILiAD Biotechnologies's last funding round?
ILiAD Biotechnologies's most recent funding round was Series B on February 10, 2026.
Who are the main investors in ILiAD Biotechnologies?
Key investors in ILiAD Biotechnologies include RA Capital Management, Knott Partners, LP, SDS Capital Group, European Union.
Will ILiAD Biotechnologies IPO soon?
No public IPO plans have been announced for ILiAD Biotechnologies.
How can I track ILiAD Biotechnologies secondary market activity?
Caplight tracks bids, offers, and trades in ILiAD Biotechnologies's shares on secondary markets.